Abstract

Increased glucose uptake and metabolism is a prominent phenotype of most cancers, but efforts to clinically target this metabolic alteration have been challenging. Here, we present evidence that lactoylglutathione (LGSH), a byproduct of methylglyoxal detoxification, is elevated in both human and murine non-small cell lung cancers (NSCLC). Methylglyoxal is a reactive metabolite byproduct of glycolysis that reacts non-enzymatically with nucleophiles in cells, including basic amino acids, and reduces cellular fitness. Detoxification of methylglyoxal requires reduced glutathione (GSH), which accumulates to high levels in NSCLC relative to normal lung. Ablation of the methylglyoxal detoxification enzyme glyoxalase I (Glo1) potentiates methylglyoxal sensitivity and reduces tumor growth in mice, arguing that targeting pathways involved in detoxification of reactive metabolites is an approach to exploit the consequences of increased glucose metabolism in cancer.

Details

Title
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
Author
Luengo, Alba 1   VIAFID ORCID Logo  ; Abbott, Keene L 1   VIAFID ORCID Logo  ; Davidson, Shawn M 2 ; Hosios, Aaron M 1 ; Faubert, Brandon 3   VIAFID ORCID Logo  ; Sze Ham Chan 4 ; Freinkman, Elizaveta 4 ; Zacharias, Lauren G 3 ; Mathews, Thomas P 5 ; Clish, Clary B 6   VIAFID ORCID Logo  ; DeBerardinis, Ralph J 7 ; Lewis, Caroline A 4   VIAFID ORCID Logo  ; Vander Heiden, Matthew G 8   VIAFID ORCID Logo 

 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA 
 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA; Broad Institute of MIT and Harvard University, Cambridge, MA, USA 
 Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA 
 Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA, USA 
 Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA 
 Broad Institute of MIT and Harvard University, Cambridge, MA, USA 
 Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Pediatrics and Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, USA 
 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA; Broad Institute of MIT and Harvard University, Cambridge, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA 
Pages
1-11
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2322188008
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.